We’ve got two things to look at today: 1 article and 1 abstract.
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo Article originally appearing in Nature
Evidence of Remyelination with the Anti-LINGO-1 Monoclonal Antibody BIIB033 After Acute Optic Neuritis Abstract originally presented at the Annual American Academy of Neurology meeting this week.
This is some exciting stuff. I can’t really tell from the little free blurbs if these are talking about the same drug or something different. These are two different groups of researchers though; however, I would bet that they are at least in the same class of drugs.
No matter, this is big new for MS folk. The possibility of reversing the damaging effects of this erroneous immunoresponse would be fantastic!
What happens in MS is that the person’s own body attacks the insulation around their nerves. Without the insulation, the signals going down the nerve don’t go as fast, leading to slow signals. This typically manifests in a variety of functional symptoms, including weakness, stiffness, sensory problems, vision problems, fatigue.
So this medicine they’re looking at would rebuild the nerve cells’ insulation and hopefully also reverse (or at least reduce) those functional symptoms as well! I’ll be excited to see where this goes!